Here are the Form 4 insider transactions from Mural Oncology plc (MURA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MURA filings page.
Mural Oncology plc disclosed that a director reported the cancellation of stock options in connection with the company’s sale. Under a Transaction Agreement dated August 20, 2025, XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty Corporation, acquired all the issued and to be issued share capital of Mural Oncology for a cash purchase price of $2.035 per share, with the acquisition completed as of December 5, 2025 (the Effective Time).
At the Effective Time, each option to purchase ordinary shares with an exercise price per share equal to or greater than the $2.035 Scheme Consideration was cancelled and ceased to be outstanding, and no cash was delivered for those options. The report lists stock options to buy 8,637 ordinary shares at $2.56 expiring on June 10, 2035, 8,462 shares at $3.35 expiring on May 29, 2034, and 15,021 shares at $3.61 expiring on December 13, 2033, all of which now show zero derivative securities beneficially owned.
Mural Oncology plc director George Golumbeski reported the cancellation of two stock option grants in connection with the company’s acquisition by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty Corporation. The transaction transferred all issued and to‑be‑issued Mural shares for a cash purchase price of $2.035 per share, completed on December 5, 2025.
At closing, 8,637 options with a $2.56 exercise price and 15,334 options with a $3.38 exercise price, each for ordinary shares, were canceled and ceased to be outstanding. Under the agreement, options with exercise prices equal to or greater than the $2.035 per share consideration received no cash payment when they were canceled.
Mural Oncology plc director Sachiyo Minegishi reported the cancellation of stock options in connection with the company’s acquisition by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty Corporation. Under a Transaction Agreement dated August 20, 2025, XRA 5 Corp. acquired all Mural Oncology share capital for cash of $2.035 per share. At the December 5, 2025 effective time, the director’s options to buy 8,637 ordinary shares at $2.56 per share and 15,335 ordinary shares at $3.38 per share were disposed of and ceased to be outstanding because their exercise prices were at or above the cash consideration, so no cash payment was delivered for these options.
Mural Oncology plc reports insider equity changes tied to its cash acquisition by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty Corporation, effective December 5, 2025. Under the deal, all issued and to be issued shares of Mural Oncology were acquired for a cash price of $2.035 per ordinary share, and Chief Medical Officer Vicki L. Goodman disposed of 84,727 ordinary shares, leaving her with zero directly held shares.
The transaction also covered equity awards. A total of 71,509 unvested restricted stock units were cancelled and converted into the right to receive the same cash consideration per share. Stock options with exercise prices at or above the cash price, including options over 135,604 shares at $3.61 and 65,000 shares at $3.43, were cancelled at the effective time with no cash consideration delivered in exchange.